Trial Examines Tolerance of Maintenance Olaparib in Advanced Ovarian Cancer

June 12, 2019 5:00 pm

By Dave Levitan

An analysis of the phase III SOLO1 trial found no new safety signals when the PARP inhibitor olaparib was given as maintenance therapy for women with newly diagnosed advanced ovarian cancer and a BRCA mutation. Nausea, fatigue, … Read more

Does Maintenance Rucaparib Improve Post-Progression Outcomes in Ovarian Cancer?

June 10, 2019 7:00 pm

By Dave Levitan

Maintenance therapy with the PARP inhibitor rucaparib offered improved post-progression outcomes in a phase III trial of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who were in a complete or partial response to … Read more

SOLO3 Examines Benefit of Olaparib vs Chemo in Platinum-Sensitive Relapsed Ovarian Cancer

June 5, 2019 8:00 pm

By Leah Lawrence

Patients with BRCA-mutated, platinum-sensitive relapsed ovarian cancer derived significant clinical benefit from treatment with olaparib monotherapy compared with treatment of physician’s choice, according to the results of the SOLO3 trial, a US Food and Drug Administration … Read more

Benefit of Single-Agent Carboplatin in Vulnerable, Elderly Patients With Ovarian Cancer

June 5, 2019 7:00 pm

By Leah Lawrence

Single-agent carboplatin conferred significantly worse survival outcomes in vulnerable, elderly patients with stage III/IV epithelial ovarian cancer compared with weekly or every 3 weeks carboplatin/paclitaxel, according to results of the EWOC-1 trial (abstract 5508), which … Read more

Chemo-Free Combo Boosts PFS in Recurrent Ovarian Cancer

June 4, 2019 6:00 pm

By Ian Ingram

Benefit seen across all subgroups for patients with platinum-sensitive disease.

Ovarian cancer patients with recurrent, platinum-sensitive disease experienced a longer interval without disease progression when bevacizumab (Avastin) was added to niraparib (Zejula), a phase II study found.… Read more

Study Shows Ovarian Cancer Survival Increase

May 3, 2019 5:00 pm

A gynecologic oncologist at the Stephenson Cancer Center at OU Medicine was a national leader of a newly published research study that reveals good news for women with ovarian cancer—longer survival times plus a treatment option that causes fewer difficult … Read more

Still No Benefit of IP Chemo for Ovarian Cancer

April 24, 2019 5:00 pm

By Charles Bankhead

No PFS or OS benefit, more toxicity with IP verses IV regimens

Final results of a highly anticipated randomized trial failed to show a survival benefit with intraperitoneal (IP) chemotherapy in patients with newly diagnosed advanced ovarian … Read more

Niraparib Offers New Option in Heavily Pretreated Ovarian Cancer

April 17, 2019 7:00 pm

By Dave Levitan

Niraparib showed promising and clinically relevant activity as therapy for heavily pretreated patients with ovarian cancer, according to a new phase II study. This was particularly true among women with homologous recombination deficiency (HRD)-positive tumors.

“Although most … Read more

Initial Phase 2 Data From an IMV Clinical Study Continues to Demonstrate DPX-Survivac’s Prior Trend as a Potential Monotherapy Treatment for Advanced Ovarian Cancer

March 26, 2019 5:00 pm

IMV Inc., a clinical stage immuno-oncology corporation, today announced preliminary data from the phase 2 cohort of the DECIDE clinical study. Six patients receiving DPX-Survivac monotherapy with intermittent low-dose cyclophosphamide (mCPA) have reached the first CT scan assessment with key … Read more

SGO 2019: Maintenance Rucaparib Effective for All Age Groups in Ovarian Cancer

March 22, 2019 5:00 pm

By Christina Bennett, MS

Rucaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, was effective as a maintenance therapy across all age groups of patients with recurrent ovarian cancer, according to the results of a post-hoc exploratory analysis of ARIEL3 presented at … Read more

‘End of the Road’ for Trabectedin in Ovarian Cancer?

March 21, 2019 7:00 pm

By Ian Ingram

Trial stopped for futility, but 13-month OS improvement seen in patients with BRCA mutations.

Trabectedin (Yondelis) plus pegylated liposomal doxorubicin (PLD) failed to improve survival in a phase III trial of third-line ovarian cancer, but a survival … Read more

Avelumab Combo Falls Short in Advanced Ovarian Cancer

March 20, 2019 7:00 pm

By Ian Ingram

But showed promise in PD-L1-positive group.

Adding avelumab (Bavencio) to pegylated liposomal doxorubicin (PLD) failed to improve survival outcomes for patients with platinum-resistant or refractory ovarian cancer in a phase III trial reported here.

In the intent-to-treat … Read more

Early Data Send Strong Signal in Advanced Gyn Cancers

March 19, 2019 7:00 pm

By Ian Ingram

Clinical benefit rate tops 90% in pair of single-center studies.

Two early trials of novel combinations showed promising clinical activity in gynecologic cancers at a late-breaking abstract session at the Society of Gynecologic Oncology (SGO) meeting here.… Read more

SGO 2019: Pembrolizumab Combo Shows Clinical Benefit for Recurrent Epithelial Ovarian Cancer

March 19, 2019 3:00 pm

By Christina Bennett, MS

Pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide showed clinical activity in patients with recurrent epithelial ovarian cancer, according to the results of an open-label phase II trial (LBA4) presented at the 2019 Society of … Read more

Lenvatinib Combo Yields Favorable Responses in Ovarian, Endometrial Cancers

March 18, 2019 3:30 pm

By Kristie L. Kahl

Lenvatinib (Lenvima) in combination with weekly paclitaxel induced activity among those with recurrent endometrial and platinum-resistant epithelial ovarian cancer, resulting in a 65% overall response rate (ORR), according to results from a phase I study presented … Read more

SGO 2019: Dendritic Cell-Based Immunotherapy Appears Promising for Recurrent Ovarian Cancer

March 16, 2019 5:00 pm

The treatment offers long-lasting anti-tumor immunity.

The addition of a dendritic cell immunotherapy to chemotherapy has been found to prolong overall survival significantly in patients with recurrent ovarian cancer. The combination of chemotherapy + immunotherapy corresponded to 73% survival after … Read more

Anti-CD47 Antibody Trial in Advanced Cancers Shows Treatment Appears Safe, Well-Tolerated

March 6, 2019 5:00 pm

By Krista Conger

Over the years, I’ve written quite a bit about a protein called CD47 that is found on the surface of many types of cancer cells, as well as on aging red blood cells.

In 2009, researchers in … Read more

ImmunoGen’s Ovarian Cancer Drug Misses Phase III Primary Endpoint

March 4, 2019 5:00 pm

US-based biotechnology company ImmunoGen has reported negative top-line results from the Phase III FORWARD I ovarian cancer trial of mirvetuximab soravtansine.

The study failed to meet its primary endpoint of progression-free survival (PFS). Mirvetuximab soravtansine is an antibody-drug conjugate (ADC) … Read more

Exactly What Does a Principal Investigator of a Trial Do?

February 13, 2019 8:00 pm

By Milton Packer, MD

Most observers do not understand what the academic leaders of a clinical trial really do. To many, the steering committee simply takes its marching orders from industry sponsors. Some believe that every trial is designed by … Read more

Alisertib-Based Combo Improves Survival Outcomes in Ovarian, Breast Cancer

January 21, 2019 10:30 am

By Jessica Skarzynski

For some time now, paclitaxel has been considered standard of care in the treatment of patients with platinum-resistant ovarian cancer; however, recent research has shown the addition of the investigational drug alisertib to a paclitaxel regimen demonstrated … Read more